title: Bi-directional modulation of 5-hydroxytryptamine-induced plasma extravasation in the rat knee joint by nociceptin.
abstract: The role of nociceptin, the endogenous ligand for the opioid receptor-like (ORL1) receptor, in nociceptive processing is controversial. Most studies demonstrate hyperalgesia following supraspinal administration, analgesia following intrathecal and peripheral administration at higher doses, and hyperalgesia following intrathecal and peripheral application at lower doses. The present study investigates the effect of nociceptin on synovial plasma extravasation and its ability to modulate 5-hydroxytryptamine-induced synovial plasma extravasation using the rat knee joint model of inflammation. Nociceptin alone does not alter synovial plasma extravasation from baseline. Nociceptin at concentrations up to 1 nM enhances 5-hydroxytryptamine-induced synovial plasma extravasation (up to 50%) and nociceptin at concentrations above 100 nM inhibits 5-hydroxytryptamine-induced synovial plasma extravasation (down to 45%). The novel, selective ORL1 receptor antagonist J-113397 potently inhibits the pro-inflammatory effect of nociceptin, but only partly inhibits, at higher concentrations, the anti-inflammatory effects of nociceptin.These findings demonstrate a dose-dependent bi-directional effect of nociceptin on inflammatory processes and may indicate a target for novel therapeutics.
authors: Department of Anesthesia and Perioperative Medicine, University of California at San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0464, USA.
authors: S
authors: S
authors: Grond
authors: A
authors: A
authors: Gabriel
authors: C
authors: C
authors: Pietruck
authors: L C
authors: LC
authors: Yu
authors: G X
authors: GX
authors: Xie
authors: P
authors: P
authors: Pierce Palmer
mesh_terms: D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001798:Blood Proteins / Q000378:metabolism*; D002199:Capillary Permeability / Q000187:drug effects*; D007719:Knee Joint / Q000098:blood supply*; D008297:Male; D009292:Narcotic Antagonists / Q000494:pharmacology; D018847:Opioid Peptides / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid; D012701:Serotonin / Q000494:pharmacology*; D000094942:Nociceptin Receptor; D000097629:Nociceptin
chemical_list: D001562:Benzimidazoles; D001798:Blood Proteins; D009292:Narcotic Antagonists; D018847:Opioid Peptides; D010880:Piperidines; D011957:Receptors, Opioid; D012701:Serotonin; D000094942:Nociceptin Receptor; D000097629:Nociceptin; C402921:J 113397; C000722285:Oprl1 protein, rat